

AUG 16 2004

510(k) SUMMARY

<i>Submitter</i>	<i>Contact</i>
 OsteoBiologics, Inc. 12500 Network, Suite 112 San Antonio, Texas 78249 USA	Gabriele G. Niederauer, Ph.D. Director of Research and Development Phone: 210-690-2131 (ext. 228) Fax: 210-690-2559 E-mail: gabi@obi.com

Date of Summary: November 25, 2003
Revised: August 11, 2004
Common Name: Resorbable Bone Void Filler
Proprietary Name: PolyGraft™ TCP
Device Classification: Resorbable calcium salt bone void filler (Product Code 87MQV) is a Class II device, per 21 CFR 888.3045
510(k) Number: K033707

Description of Device: PolyGraft™ TCP is manufactured using a blend of poly(D,L-lactide-co-glycolide), tricalcium phosphate, polyglycolide fibers and surfactant. The PolyGraft™ TCP will be provided in a variety of shapes and sizes ranging from small, porous granules to preformed cylindrical plugs.

Intended Use: The PolyGraft™ TCP is to be used to fill bony voids or gaps caused by trauma or surgery that are not intrinsic to the stability of the bony structure. The PolyGraft™ TCP is intended to be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process.

Substantial Equivalence: The PolyGraft™ TCP is substantially equivalent in design, function and intended use to the PolyGraft™ BGS cleared as K030288 on July 17, 2003.

Testing: Biocompatibility assessment performed by independent certified laboratories demonstrated the biocompatibility of the materials used for this device. Degradation testing performed in a simulated body fluid at 37 °C showed that the degradation rate is substantially equivalent to the predicate devices. The results from this side-by-side *in vitro* comparison demonstrated that PolyGraft™ TCP are substantially equivalent to the predicate devices, therefore supporting the suitability of the PolyGraft™ TCP for use in a clinical situation.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

AUG 16 2004

Gabriele G. Niederauer, Ph.D.
Director of Research and Development
Osteobiologics
12500 Network, Suite 112
San Antonio, TX 78249-3308

Re: K033707
Trade Name: PolyGraft TCP
Regulation Number: 21 CFR 888.3045
Regulation Name: Resorbable calcium salt bone void filler devices
Regulatory Class: Class II
Product Code: MQV
Dated: July 22, 2004
Received: July 23, 2004

Dear Dr. Niederauer:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if

applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten". The signature is written in a cursive style with a long horizontal flourish extending to the right.

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and

Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K033707

Device Name: PolyGraft™ TCP

Indications for Use:

The PolyGraft™ TCP is to be used to fill bony voids or gaps caused by trauma or surgery that are not intrinsic to the stability of the bony structure. The PolyGraft™ TCP is intended to be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process.


Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)


(Division Sign-Off)
Division of General, Restorative,
and Neurological Devices

510(k) Number K033707

Page 1 of 1